 This study found that a single dose of a lipid nanoparticle formulated unmodified mRNA vaccine encoding the rabies virus glycoprotein, RabVG, was more effective at generating a stronger immune response than two doses of Rabipu in non-human primates. This mRNA vaccine also generated higher RabVG binding and neutralizing antibody titers than Rabipu, while the degree of somatic hypermutation and clonal diversity of the response were similar for both vaccines. These results suggest that this platform has potential for the development of a broadly protective vaccine against these viruses. This article was offered by Frederica Helgren, Alberto Kajiji, Rodrigo Acavera, and others.